Everyone is chasing signals. Fundz is what comes next.
Everyone gets the same alerts the same morning. Fundz brings more than a dozen live business signals together on each company, ranks every company against your ICP, and each morning delivers the best few: who to reach out to, why, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Atrium Therapeutics has successfully closed a $50 million private placement. The funding will support the company's ongoing development efforts.
PUBLIC · RNAOct 08, 2026
Amount Raised
$50 Million
Round Type
Post-IPO Equity
San DiegoBiotechnologyHealth CareTherapeutics
Description
Atrium Therapeutics has announced a robust funding event with the closing of a $50 million private placement. This capital will be directed towards advancing their therapeutic development projects. The funding reflects strong support and confidence in the company's future. Investors involved have shown commitment to Atrium's vision.
Company Information
Company
Atrium Therapeutics
Location
San Diego, California, United States
About
Atrium Therapeutics, Inc. is a newly formed independent company resulting from the separation of Avidity Biosciences' early stage precision cardiology programs. It focuses on the development of therapeutic interventions for cardiovascular diseases leveraging its innovative programs ATR 1086 and ATR 1072. Atrium aims to advance the field of cardiology by utilizing precision medicine strategies. This company is now publicly traded following its separation from Avidity.
Fundz sees it the moment Atrium Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealth CareTherapeutics